Tetrahydro-isoquinoline-based factor Xa inhibitors

Journal of Medicinal Chemistry

Volumn 41, Issue 25, 1998, Pages 4983-4994

  Kucznierz, Ralf ^a   Grams, Frank ^a   Leinert, Herbert ^a   Marzenell, Klaus ^a   Engh, Richard A ^b   Von der Saal, Wolfgang ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(2 CARBAMIMIDOYL 1,2,3,4 TETRAHYDRO ISOQUINOLIN 7 YLOXY)[4 [1 (1 IMINOETHYL)PIPERIDIN 4 YLOXY]PHENYL]ACETIC ACID ETHYL ESTER; (2 CARBAMIMIDOYL 1,2,3,4 TETRAHYDRO ISOQUINOLIN 7 YLOXY)[4 [1 [IMINO(4 METHOXYPHENYL)METHYL]PIPERIDIN 4 YLOXY]PHENYL]ACETIC ACID; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 4 [4 [(2 CARBAMIMIDOYL 1,2,3,4 TETRAHYDRO ISOQUINOLIN 7 YLOXY)(ETHOXYCARBONYL)METHYL]PHENOXY]PIPERIDINE 1 CARBOXYLIC ACID ALLYL ESTER; [4 (1 CARBAMIMIDOYLPIPERIDIN 4 YLOXY)PHENYL](2 CARBAMIMIDOYL 1,2,3,4 TETRAHYDRO ISOQUINOLIN 7 YLOXY)ACETIC ACID; [4 (1 CARBAMIMIDOYLPIPERIDIN 4 YLOXY)PHENYL](2 CARBAMIMIDOYL 1,2,3,4 TETRAHYDRO ISOQUINOLIN 7 YLOXY)ACETIC ACID ETHYL ESTER; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BM 12 1700; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; HUMAN; NORMAL HUMAN; STRUCTURE ACTIVITY RELATION;

ANTICOAGULANTS; FACTOR XA; ISOQUINOLINES; KINETICS; MODELS, MOLECULAR; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PLASMIN; PROTEIN BINDING; SERINE PROTEINASE INHIBITORS; THROMBIN; THROMBIN TIME; TRYPSIN INHIBITORS;

EID: 0032480907     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9800402     Document Type: Article

References (42)

1. Hertzberg, M. Biochemistry of Factor X. Blood Rev. 1994, 8, 56-62.
2. Davie, E. W.; Fujikawa, K.; Kisiel, W. The Coagulation Cascade: Initiation, Maintenance, and Regulation. Biochemistry 1991, 30, 10363-10370.
3. (a) Bode, W.; Brandstetter, H.; Mather, T.; Stubbs, M. T. Comparative Analysis of Haemostatic Proteinases: Structural Aspects of Thrombin, Factor Xa, Factor IXa and Protein C. Thromb. Haemostasis 1997, 78, 501-511.
4. (b) Prasa, D.; Svendsen, L.; Stürzebecher, J. Inhibition of Thrombin Generation in Plasma by Inhibitors of Factor Xa. Thromb. Haemostasis 1997, 78, 1215-1220.
5. (c) Quan, M. L.; Pruitt, J. R.; Ellis, C. D.; Liauw, A. Y.; Galemmo, R. A., Jr.; Stouten, P. F. W.; Wityak, J.; Knabb, R. M.; Thoolen, M. J.; Wong, P. C.; Wexler, R. R. Bisbenzamidine Isoxazoline Derivatives as Factor Xa Inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 2813-2818.
6. (d.) Edmunds, J. J.; Rapundalo, S. T. Thrombin and Factor Xa Inhibition. Anna. Rep. Med. Chem. 1996, 31, 51-60.
7. (e) Stubbs, M. T. Structural Aspects of Factor Xa Inhibition. Curr. Pharm. Des. 1996, 2, 543-552.
8. (f) Wong, P. C.; Crain, E. J., Jr.; Nguan, O.; Watson C. A.; Racanelli, A. Antithrombotic Actions of Selective Inhibitors of Blood Coagulation Factor Xa in Rat Models of Thrombosis. Thromb. Res. 1996, 83, 117-126.
9. (g) Yamazaki, M. Factor Xa Inhibitors. Drugs Future 1995, 20, 911-918.
10. (h) Mao, S. Factor Xa Inhibitors. Perspec. Drug Discovery Des. 1994, 1, 423-430.
11. Waxman, L.; Smith, D. E.; Arcuri, K. E.; Vlasuk, G. P. Tick Anticoagulant Peptide (TAP) Is a Novel Inhibitor of Blood Coagulation Factor Xa. Science 1990, 248, 593-596.
12. (a) Nutt, E.; Gasic, T.; Rodkey, J.; Gasic, G. J.; Jacobs, J. W.; Friedman, P. A.; Simpson, E. The Amino Acid Sequence of Antistasin: A Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure. J. Biol. Chem. 1988, 263, 10162-10167.
13. (b) Lapatto, R.; Krengel, U.; Schreuder, H. A.; Arkema, A.; de Boer, B.; Kalk, K. H.; Hol, W. G. J.; Grootenhuis, P. D. J.; Mulders, J. W. M.; Dijkema, R.; Theunissen,;H. J. M.; Dijkstra, B. W. X-ray Structure of Antistasin at 1.9 Å Resolution and its Modelled Complex with Blood Coagulation Factor Xa. EMBO J. 1997, 16, 5151-5161.
14. Cappello, M.; Vlasuk, G. P.; Bergum, P. W.; Huang, S.; Hotez, P. J. Anclystoma Caninum Anticoagulant Peptide: A Hookworm derived Inhibitor of Human Coagulation Factor Xa. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 6152-6156.
15. Seymour, J. L.; Lindquist, R. N.; Dennis, M. S.; Moffat, B.; Yansura, D.; Reilly, D.; Wessinger, M. E.; Lazarus, R. A. Ecotin Is a Potent Anticoagulant and Reversible Tight-Binding Inhibitor of Factor Xa. Biochemistry 1994, 33, 3949-3958.
16. von der Saal, W.; Engh, R. A.; Eichinger, A.; Gabriel, B.; Kucznierz, R.; Sauer, J. Syntheses and Selective Inhibitory Activities of Terphenyl-Bisamidines for Serine Proteases. Arch. Pharmacol. Pharm. Med. Chem. 1996, 329, 73-82.
17. (a) Tidwell, R. R.; Webster, W. P.; Shaver, S. R.; Geratz, J. D. Strategies for Anticoagulation with Synthetic Protease Inhibitors: Xa Inhibitors Versus Thrombin Inhibitors. Thromb. Res. 1980, 19, 339-349.
18. (b) Stürzebecher, J.; Stürzebecher, U.; Vieweg, H.; Wagner, G.; Hauptmann, J.; Markwardt, F. Synthetic Inhibitors of Bovine Factor Xa and Thrombin: Comparison of Their Anticoagulant Efficiency. Thromb. Res. 1989, 54, 245-252.
19. Very recently a novel series of bis-phenylamidine carboxylate-derived inhibitors of factor Xa has been published: Maduskuie, T. P., Jr.; McNamara, K. J.; Ru, Y.; Knabb, R. M.; Stouten, P. F. W. Rational Design and Synthesis of Novel, Potent Bisphenylamidine Carboxylate Factor Xa Inhibitors. J. Med. Chem. 1998, 41, 53-62.
20. (a) Katakura, S.; Nagahara, T.; Hara, T.; Iwamoto, M. A Novel Factor Xa Inhibitor: Structure-Activity Relationships and Selectivity Between Factor Xa and Thrombin. Biochem. Biophys. Res. Commun. 1993, 197, 965-972.
21. (b) Nagahara, T.; Yokoyama, Y.; Inamura, K.; Katakura, S.; Komoriya, S.; Yamaguchi, H.; Hara, T.; Iwamoto, M. Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors. J. Med. Chem. 1994, 37, 1200-1207.
22. (c) Hara, T.; Yokoyama, A.; Ishihara, H.; Yokoyama, Y.; Nagahara, T.; Iwamoto, M. DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa. Thromb. Haemostasis 1994, 71, 314-319.
23. (d) Hara, T.; Yokoyama, A.; Tanabe, K.; Ishihara, H.; Iwamoto, M. DX-9065a, an Orally Active, Specific Inhibitor of Factor Xa, Inhibits Thrombosis without Affecting Bleeding Time in Rats. Thromb. Haemostasis 1995, 74, 635-639.
24. (e) Hara, T.; Yokoyama, A.; Tanabe, K.; Ishihara, H.; Iwamoto, M. Molecular Model of an Interaction Between Factor Xa and DX-9065a, a Novel Factor Xa Inhibitor: Contribution of The Acetimidoylpyrrolidine moiety of The Inhibitor To Potency and Selectivity for Serine Proteases. Eur. J. Med. Chem. 1995, 30, 387-394.
25. For an improved synthesis of DX-9065a, see: Kehr, C.; Neidlein, R.; Engh, R. A.; Brandstetter, H.; Kucznierz, R.; Leinert, H.; Marzenell, K.; Strein, K.; von der Saal, W. A Short Synthesis of the Factor Xa Inhibitor DX-9065a Using Palladium-Catalyzed Key Steps. Helv. Chim. Acta 1997, 80, 892-896.
26. Padmanabhan, K.; Padmanabhan, K. P.; Tulinsky, A.; Park, C. H.; Bode. W.; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kisiel, W. Structure of Human Des(1-45) Factor Xa at 2.2 Å Resolution. J. Mol. Biol. 1993, 232, 947-966.
27. Brandstetter, H.; Kühne, A.; Bode, W.; Huber, R.; von der Saal, W.; Wirthensohn, K.; Engh, R. A. X-ray Structure of Active Site-inhibited Clotting Factor Xa: Implications for Drug Design and Substrate Recognition. J. Biol. Chem. 1996, 271, 29988-29992.
28. Bevis, M. J.; Forbest, E. J.; Naik, N. N.; Uff, B. C. The Synthesis of Isoquinolines, Indoles and Benzthiophen by an Improved Pomeranz-Fritsch Reaction Using Boron Trifluoride in Trifluoroacetic Anhydride. Tetrahedron 1971, 27, 1253-1259.
29. For reviews on Mitsunobu reactions, see: (a) Hughes, D. L. The Mitsunobu Reaction. Org. React. 1992, 42, 335-656. (b) Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1-28.
30. For reviews on Mitsunobu reactions, see: (a) Hughes, D. L. The Mitsunobu Reaction. Org. React. 1992, 42, 335-656. (b) Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1-28.
31. Bernatowicz, M. S.; Wu, Y.; Matsueda, G. R. 1H-Pyrazole-1-carboxamidine Hydrochloride: An Attractive Reagent for Guanylation of Amines and Its Application to Peptide Synthesis. J. Org. Chem. 1992, 57, 2497-2502.
32. Kunz, H.; Unverzagt, C. Der Allyloxycarbonyl(Aloc)-Rest - die Verwandlung einer untauglichen in eine wertvolle Aminoschutzgruppe für die Peptidsynthese. Angew. Chem. 1984, 96, 426-427.
33. The application of pyrrolidine as an allyl scavenger in the palladium-catalyzed cleavage of allyl carbamates has been reported recently: (a) Howard, P. W.; Thurston, D. E. The Use of Carbamate Protecting Groups in the Synthesis of Monomeric and Dimeric Pyrrolor[2,1-c]benzodiazepines. J. Pharm. Pharmacol 1995, 1078. (b) See also: Roos, E. C.; Bernabé, P.; Hiemstra, H.; Speckamp, W. N. Palladium-Catalyzed Transprotection of Allyloxycarbonyl-Protected Amines: Efficient One-Pot Formation of Amides and Dipeptides. J. Org. Chem. 1995, 60, 1733-1740.
34. The application of pyrrolidine as an allyl scavenger in the palladium-catalyzed cleavage of allyl carbamates has been reported recently: (a) Howard, P. W.; Thurston, D. E. The Use of Carbamate Protecting Groups in the Synthesis of Monomeric and Dimeric Pyrrolor[2,1-c]benzodiazepines. J. Pharm. Pharmacol 1995, 1078. (b) See also: Roos, E. C.; Bernabé, P.; Hiemstra, H.; Speckamp, W. N. Palladium-Catalyzed Transprotection of Allyloxycarbonyl-Protected Amines: Efficient One-Pot Formation of Amides and Dipeptides. J. Org. Chem. 1995, 60, 1733-1740.
35. The enamine derivative of 20 has not been detected under these conditions, not even in traces. This is attributed to the generally enhanced tendency of pyrrolidines to form enamines.
36. Dangles, O.; Guibé, F.; Balavoine, G.; Lavielle, S.; Marquet, A. Selective Cleavage of the Allyl and Allyloxycarbonyl Groups through Palladium-Catalyzed Hydrostannolysis with Tributyltin Hydride: Application to the Selective Protection-Deprotection of Amino Acid Derivatives and in Peptide Synthesis. J. Org. Chem. 1987, 52, 4984-4993.
37. Concerning the nomenclature of the subsites of fXa, see ref 14.
38. Hilpert, K.; Ackermann, J.; Banner, D. W.; Gast, A.; Gubernator, K.; Hadváry, P.; Labler, L.; Müller, K.; Schmid, G.; Tschopp, T. B.; van de Waterbeemd, H. Design and Synthesis of Potent and Highly Selective Thrombin Inhibitors. J. Med. Chem. 1994, 37, 3889-3901.
39. For the MD all residues of the S1 pocket were allowed to move freely. All other residues were kept fixed. Solvents have not been used. Trajectories were not written out, but the movement of the residues was followed on the screen. For docking experiments the inhibitors were manually adjusted and minimized to convergence using the CVFF force field of the Insight II/Discover (MSI, San Diego, CA) program package. The protein atoms were fixed for this purpose, and a constraint was given from the exocyclic amino nitrogen atoms to Asp189 in the S1 pocket.
40. Stubbs, M. T.; Huber, R.; Bode, W. Crystal Structures of Factor Xa Specific Inhibitors in Complex with Trypsin: Structural Grounds for Inhibition of Factor Xa and Selectivity Against Thrombin. FEBS Lett. 1995, 375, 103-107.
41. iplasmin = 13, μM.
42. Engh, R. A.; Brandstetter, H.; Sucher, G.; Eichinger, A.; Baumann, U.; Bode, W.; Huber, R.; Poll, T.; Rudolph, R.; von der Saal, W. Enzyme Flexibility, Solvent and Weak Interactions Characterize Thrombin-Ligand Interactions: Implications for Drug Design. Structure 1996, 4, 1353-1362.